🔗 Visit the ClinicalTrials.gov page for NCT03509246
Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | Integrated genomic analyses of ovarian carcinoma. | Nature | 2011 | 47.72 |
2 | Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. | J Clin Oncol | 2007 | 3.54 |
3 | Synthetic lethality between CCNE1 amplification and loss of BRCA1. | Proc Natl Acad Sci U S A | 2013 | 1.22 |
4 | FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy. | Clin Cancer Res | 2015 | 1.22 |